Bangkok Dusit Medical Services Public Company Limited
Bangkok Dusit Medical Services Public Company Limited (BDULF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Bangkok Dusit Medical Services Public Company Limited (BDULF), featuring income statements, balance sheets, and cash flow data.
Bangkok Dusit Medical Services Public Company Limited (BDULF) Income Statement & Financial Overview
Analyze Bangkok Dusit Medical Services Public Company Limited’s BDULF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $28.08B | $27.40B | $28.15B | $25.70B |
| Cost of Revenue | $17.69B | $17.04B | $17.63B | $16.66B |
| Gross Profit | $10.40B | $10.37B | $10.52B | $9.04B |
| Gross Profit Ratio | $0.37 | $0.38 | $0.37 | $0.35 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.15B | $5.48B | $5.31B | $5.15B |
| Operating Expenses | $4.77B | $5.04B | $4.91B | $4.77B |
| Total Costs & Expenses | $22.83B | $22.50B | $22.93B | $21.81B |
| Interest Income | $31.40M | $39.02M | $40.17M | $47.46M |
| Interest Expense | $97.12M | $107.87M | $102.42M | $110.56M |
| Depreciation & Amortization | $1.62B | $1.60B | $1.55B | $1.50B |
| EBITDA | $7.30B | $6.99B | $7.22B | $5.82B |
| EBITDA Ratio | $0.26 | $0.26 | $0.26 | $0.23 |
| Operating Income | $5.62B | $5.32B | $5.61B | $4.27B |
| Operating Income Ratio | $0.20 | $0.19 | $0.20 | $0.17 |
| Other Income/Expenses (Net) | -$47.13M | -$43.68M | -$38.33M | -$49.05M |
| Income Before Tax | $5.58B | $5.28B | $5.57B | $4.22B |
| Income Before Tax Ratio | $0.20 | $0.19 | $0.20 | $0.16 |
| Income Tax Expense | $1.08B | $840.60M | $1.15B | $756.08M |
| Net Income | $4.35B | $4.33B | $4.25B | $3.33B |
| Net Income Ratio | $0.15 | $0.16 | $0.15 | $0.13 |
| EPS | $0.27 | $0.27 | $0.27 | $0.21 |
| Diluted EPS | $0.27 | $0.27 | $0.27 | $0.21 |
| Weighted Avg Shares Outstanding | $15.89B | $15.89B | $15.89B | $15.89B |
| Weighted Avg Shares Outstanding (Diluted) | $15.89B | $15.89B | $15.89B | $15.89B |
The company's financials show resilient growth, with revenue advancing from $25.70B in Q2 2024 to $28.08B in Q1 2025. Gross profit remained healthy with margins at 37% in Q1 2025 compared to 35% in Q2 2024. Operating income hit $5.62B last quarter, sustaining a consistent 20% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $7.30B. Net income rose to $4.35B, while earnings per share reached $0.27. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan